Results 71 to 80 of about 5,551,009 (351)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S, Cappuzzo, F, Cartenì, G, Cognetti, F, Cortesi, E, De Giglio, A, De Giorgi, U, Giannarelli, D, Panni, S, Pazzola, A, Porta, C, Procopio, G, Raimondi, A, Rastelli, F, Rossetti, S, Sabbatini, R, Sobrero, A, Sternberg, Cn, Surico, G, Tassinari, D, Tortora, G, Turci, D, Verzoni, E   +22 more
core   +3 more sources

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]

, 2020
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David, Barkauskas, Donald A, Gatalica, Zoran, Kurzrock, Razelle, Nikanjam, Mina, Swensen, Jeff   +5 more
core   +2 more sources

Modulating Treg stability to improve cancer immunotherapy.

Trends in Cancer, 2023
Immunosuppressive regulatory T cells (Tregs) provide a main mechanism of tumor immune evasion. Targeting Tregs, especially in the tumor microenvironment (TME), continues to be investigated to improve cancer immunotherapy.
J. Kang, R. Zappasodi
semanticscholar   +1 more source

Biomarkers in Cancer Immunotherapy [PDF]

Cancer Cell, 2015
Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer ...
Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M   +2 more
openaire   +4 more sources

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer

Cancer Immunology, Immunotherapy
Background Local recurrence after surgical resection is a major clinical challenge in patients with advanced head and neck cancer (HNC). We previously reported using transfer of a flap treated with dendritic cells (DCs) (“immuno-flap”) as a novel cancer ...
Hiroaki Mori, Yasuto Akiyama, Chie Maeda, Akari Kanematsu, Tadashi Ashizawa, Kazue Yamashita, Haruo Miyata, Akira Iizuka, Tomoatsu Ikeya, Yoshichika Yasunaga, Jun Araki   +10 more
doaj   +1 more source

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

Journal for ImmunoTherapy of Cancer, 2019
Background Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy.
A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor, Kunle Odunsi   +11 more
doaj   +1 more source

Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer. [PDF]

, 2019
Human (gamma delta) γδ T cells are unconventional innate-like lymphocytes displaying a broad array of anti-tumor activities with promising perspectives in cancer immunotherapy.
Bruni E, Cazzetta V, Cimino M, Dieli F, Donadon M, Leonardi G, Mavilio D., Mikulak J, Spata G, Torzilli G   +9 more
core   +1 more source

Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology [PDF]

, 2020
Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive.
Akhmetzyanova, Ilseyar [u.v.m.], David, Paul David, Drabczyk-Pluta, Malgorzata, Gruber, Achim D., Honke, Nadine, Kershaw, Olivia, Knuschke, Torben, Megger, Dominik A., Pastille, Eva, Werner, Tanja   +9 more
core   +1 more source

Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

Cell Death and Disease
The interplay between extracellular matrix (ECM) stiffness and the tumor microenvironment is increasingly recognized as a critical factor in cancer progression and the efficacy of immunotherapy.
Zizhao Mai, Yunfan Lin, Pei Lin, Xinyuan Zhao, Li Cui   +4 more
semanticscholar   +1 more source